Showing results (541-550 of 592) with videos related to
Sort By:
Pageof 60
Lung Cancer (Amsterdam, Netherlands)|May 18, 2025
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)Francesco Facchinetti, Andrea Camerini, Chiara Bennati, et al.Lung Cancer (Amsterdam, Netherlands)|December 29, 2023
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access programFrancesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, et al.Plos One|September 5, 2015
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast CancerStefania Gori, Alessandro Inno, Elena Fiorio, et al.Cancers|October 14, 2022
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic ImplicationsMichele Simbolo, Giovanni Centonze, Luca Giudice, et al.Journal of the National Cancer Institute|May 1, 2019
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Tomás Pascual, Carmine De Angelis, et al.BMC Cancer|June 13, 2023
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN studyFilippo Lococo, Luca Boldrini, Charles-Davies Diepriye, et al.Journal of the National Cancer Institute. Monographs|November 2, 2011
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010)Alfredo Berruti, Daniele Generali, Manfred Kaufmann, et al.Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.The Lancet. Oncology|November 5, 2020
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, Valentina Guarneri, Laia Paré, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2025
The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome TrialAndrea Botticelli, Chiara Cremolini, Simone Scagnoli, et al.Pageof 60